Preliminary result of phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small-cell lung cancer in chinese patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 487-490

  Hsu, Jen Wen ^a   Hsu, Jeng Yuang ^a   Chiang, Chi Der ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cisplatin; Non small cell lung cancer; Paclitaxel

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 0031724738     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00014     Document Type: Article

References (16)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Rankin EM. Non-small cell lung cancer. In: Slevin ML, Staquet MJ, eds. Randomized trials in cancer: a critical review. New York: Raven Press, 1986;447-92.
3. Rudd R. Chemotherapy in the treatment of non-small cell lung cancer. J Respir Dis 1991;7:12-5.
4. Bunn PA Jr, Kelly K. New treatment agents for advanced small cell and non-small cell lung cancer. Semin Oncol 1995;22(suppl 6):53-63.
5. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
6. Chang AY, Kim K, Click J, et al. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-94.
7. Murphy WK, Fossella F, Winn RT, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
8. Oken MM, Creech RH, Tormey DC, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
9. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
10. Johnson DH, Chang AY, Ettinger DS. Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience. Ann Oncol 1994;5(suppl 6):45-50.
11. Belli L, Le Chevalier T, Gottfried M, et al. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Semin Oncol 1995;22(suppl 15):29-33.
12. Klastersky J, Sculier JP, European Lung Cancer Working Party. Dose finding study of paclitaxel (taxol) plus cisplatin in patients with non-small cell lung cancer. Lung Cancer 1995;12:117-25.
13. von Pawel J, Wagner H, Niederle N, et al. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin Oncol 1996;23(suppl 16):47-50.
14. Pirker R, Krajnik G, Zochbauer S, et al. Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann Oncol 1995;6:833-5.
15. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etopodise, cisplatin versus taxol with cisplatin-G-CSF versus taxol-cisplatin in advanced non-small cell lung cancer. an Eastern Cooperative Oncology Group (ECOG) trial [Abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:382.
16. Rowinsky E, Donehower R, Paclitaxel. N Engl J Med 1995;332:1004-14.